An FDA advisory committee voted Tuesday in favor of the safety and effectiveness of Insmed’s NDA amikacin for treatment of nontubercuolous mycobacterial (NTM) lung disease for patients with limited treatment options. But the panel rejected it for adult patients as a whole.
Source: Drug Industry Daily